1. Exclusions based on severe comorbidities such as asthma were used -- so there is a flaw in the study that it is not examining those whom are at the greatest risk of disease
2. In the present study, a 5 day course of ivermectin did not improve clinical and microbiological outcomes of patients with mild or moderate COVID-19 infection.
The secondary outcome of shortened symptoms is not statistically significant.
Overall this supports Ivermectin as a class 2B intervention -- if not lower. It does not demonstrate any superiority in clinical and microbiological outcomes and excludes those whom are at highest risks. At best, an equivocal study.
See Posts #14, #17 and #24.
The dosage of Ivermectin used in this study is way below the one recommended by the protocols used by the doctors of FLCCC.